SureTrader Advertisement SureTrader
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 618
Posts 92,332
Boards Moderated 28
Alias Born 09/05/02
160x600 placeholder
Stocks End Higher; Nasdaq Snaps 7-day Losing Streak
Apple sees longest string of daily losses in 18 years Stocks closed higher and near session highs Monday, with the Nasdaq Composite...
Top Equities Stories Of The Day
Deutsche Bank North America CEO Jacques Brand to Leave for PJT Partners
Apple in Long Losing Streak
Ackman: No Plans to Sell Any Valeant `Crown Jewel' Assets -CNBC
Amazon Kindle Oasis Video Review: Up Close With the Luxury E-Reader
Brazilian Judge Puts Temporary Ban on WhatsApp -- Update
Ford Profit Doubles as New Models Soar -- WSJ
Abbott to Acquire St. Jude -- WSJ
Baker Hughes Outlines Cost Cuts as Halliburton Deal Dies
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19308 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist